Celyad Oncology (CYAD) H1 2024 earnings summary

Executive summary

• Focused on advancing proprietary CAR T-cell therapy platforms and monetizing intellectual property through partnerships.

• Achieved proof-of-concept for multiplex shRNA and multispecific NKG2D-based CAR T-cell platforms.

• Re-initiated manufacturing and commercialization of C-Cath® catheter for cardiac applications.

• Operational expenses aligned with budget, supporting a cash runway into Q3 2025.

Financial highlights

• Revenue for H1 2024 was €0.1 million.

• Net loss for H1 2024 was €3.0 million, or €(0.07) per share, down from €3.7 million, or €(0.17) per share, in H1 2023.

• R&D expenses decreased to €1.5 million from €2.1 million year-over-year, reflecting strategic focus on early-stage research.

• General and administrative expenses fell to €1.7 million from €3.7 million year-over-year, mainly due to headcount reduction and lower insurance costs.

• Net cash used in operations was €2.8 million, down from €8.3 million in H1 2023.

Outlook and guidance

• Cash and cash equivalents of €6.2 million as of June 30, 2024, expected to fund operations into Q3 2025.

• Anticipates more data and possible clinical evaluation of CAR and shRNA multiplex platforms, potentially through partnerships.

• Plans to appoint a new CEO in H2 2024.